Q9BYF1 (ACE2_HUMAN) Homo sapiens (Human)
Angiotensin-converting enzyme 2 UniProtKBInterProSTRINGInteractive Modelling
805 aa; Sequence (Fasta) ; (Isoform 3)
It is possible new templates exist for this target since these models were created.
Available Structures
250 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| ACE2 -Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker |
Heteromer Q695T7; | 14×NAG; 10×NAG; 2×ZN; | ||||
| Assess | ||||||
| SIT1-ACE2-BA.2 RBD |
Heteromer P0DTC2; Q9NP91; | 16×NAG; 6×NAG; 6×3PH; 2×ZN; | ||||
| Assess | ||||||
| SIT1-ACE2-BA.5 RBD |
Heteromer P0DTC2; Q9NP91; | 16×NAG; 6×NAG; 6×3PH; 2×ZN; | ||||
| Assess | ||||||
| ACE2-SIT1 complex bound with proline |
Heteromer Q9NP91; | 14×NAG; 4×NAG; 2×ZN; 2×PRO; 2×CL; | ||||
| Assess | ||||||
| ACE2-B0AT1 complex |
Heteromer Q695T7; | 14×NAG; 10×NAG; 4×3PH; 2×ZN; | ||||
| Assess | ||||||
| ACE2-B0AT1 complex bound with glutamine |
Heteromer Q695T7; | 14×NAG; 10×NAG; 2×ZN; 2×GLN; | ||||
| Assess | ||||||
| ACE2-B0AT1 complex bound with methionine |
Heteromer Q695T7; | 14×NAG; 10×NAG; 2×ZN; 2×MET; | ||||
| Assess | ||||||
| Conformation 1 of S-ACE2-B0AT1 ternary complex |
Heteromer P0DTC2; Q695T7; | 58×NAG; 64×NAG; 2×LEU; 2×ZN; | ||||
| Assess | ||||||
| ACE2-B0AT1 complex, open conformation |
Heteromer Q695T7; | |||||
| Assess | ||||||
| The 2019-nCoV RBD/ACE2-B0AT1 complex |
Heteromer P0DTC2; Q695T7; | 14×NAG; 2×NAG; 10×NAG; 2×LEU; 2×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of human ACE2 receptor bound to protein encoded by vaccine candidate BNT162b1 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| The complex structure of RshSTT182/200 RBD bound to human ACE2 |
Heteromer | 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structure of the human ACE2 receptor in complex with antibody Fab fragment, 05B04 |
Heteromer | 2×NAG; 1×NAG; 3×NAG; | ||||
| Assess | ||||||
| RBD of SARS-CoV2 spike protein with ACE2 decoy |
Heteromer P0DTC2; | 2×NAG; 2×NAG; 1×NAG; 1×NAG; 1×ZN; 1×SO4; | ||||
| Assess | ||||||
| Native Human Angiotensin Converting Enzyme-Related Carboxypeptidase (ACE2) |
Heteromer | 3×NAG; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 |
Heteromer P0DTC2; | 1×ZN; 1×CL; 5×NAG; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 omicron RBD and human ACE2 |
Heteromer P0DTC2; | 1×NAG; 1×ZN; 1×CL; 4×NAG; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus human … |
Heteromer P59594; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS coronavirus spike receptor-binding domain complexed with its receptor |
Heteromer P59594; | 1×NAG; 4×NAG; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus civet … |
Heteromer P59594; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Inhibitor Bound Human Angiotensin Converting Enzyme-Related Carboxypeptidase (ACE2) |
Heteromer | 2×NAG; 1×CL; 1×ZN; 1×XX5; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus civet … |
Heteromer P59594; Q56NL1; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor binding domain of escape mutant SARS-CoV-2 from immunoc… |
Heteromer P0DTC2; | 1×NAG; 2×NAG; 1×NAG; 1×NAG; 1×NAG; 1×ZN; 1×CL; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from the 2002-2003 SARS coronavirus cive… |
Heteromer P59594; Q56NL1; | 5×NDG; 2×ZN; 2×CL; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of human ACE2 and GX/P2V RBD |
Heteromer A0A6G6A2Q2; | 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39 |
Heteromer P0DTC2; | 2×NAG; 2×NAG; 1×NAG; 1×NAG; 1×ZN; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2 |
Heteromer P0DTC2; | 3×NAG; 1×ZN; 1×EDO; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 |
Heteromer P0DTC2; | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 … |
Heteromer P0DTC2; | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| Receptor-binding domain (RBD) of the spike protein of the bat coronavirus RaTG13 virus in complex w… |
Heteromer A0A6B9WHD3; | 2×NAG; 3×NAG; | ||||
| Assess | ||||||
| Receptor-binding domain (RBD) of the spike protein of the bat coronavirus RaTG13 virus in complex w… |
Heteromer A0A6B9WHD3; | 2×NAG; 3×NAG; | ||||
| Assess | ||||||
| SARS-COV-2 Spike RBDMACSp25 binding to hACE2 |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of Omicron S-ACE2, C2 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-RBD-ACE2 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conform… |
Heteromer P59594; | |||||
| Assess | ||||||
| Cryo-EM structure of human ACE2 and GX/P2V/2017 RBD |
Heteromer A0A6G6A2Q2; | 1×ZN; 5×NAG; | ||||
| Assess | ||||||
| Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conform… |
Heteromer P59594; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C3 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Cryo-EM structure of Human ACE2 bound to a high-affinity SARS CoV-2 mutant |
Heteromer P0DTC2; | 3×NAG; | ||||
| Assess | ||||||
| The structure of FC08 Fab-hA.CE2-RBD complex |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron BA.2) in complex with PD of ACE2 |
Heteromer P0DTC2; | 38×NAG; 28×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron BA.3) in complex with three PD of ACE2 |
Heteromer P0DTC2; | 38×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S-ACE2 complex |
Heteromer P0DTC2; | 18×NAG; 36×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C2 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C1 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Trypsin-cleaved and low pH-treated SARS-CoV spike glycoprotein and ACE2 complex, ACE2-bound conform… |
Heteromer P59594; | |||||
| Assess | ||||||
| SARS-COV-2 Spike RBDMACSp6 binding to hACE2 |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron) in complex with PD of ACE2 |
Heteromer P0DTC2; | 23×NAG; 45×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV2 RBD-ACE2 complex |
Heteromer P0DTC2; | 1×ZN; 1×CL; 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta S-RBD-ACE2 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| S-ECD (Omicron BA.3) in complex with two PD of ACE2 |
Heteromer P0DTC2; | 33×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C2a |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein with human ACE2 (focus refinement on RBD-1/AC… |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-RBD-ACE2 complex |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| S-ECD (Omicron BA.5) in complex with PD of ACE2 |
Heteromer P0DTC2; | 38×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| ACE2-RBD in SARS-CoV-2 Kappa variant S-ACE2 complex |
Heteromer P0DTC2; | 1×ZN; 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Cryo-EM structure of human ACE2 and GD/1/2019 RBD |
Heteromer A0A7D6PMV8; | 1×ZN; 4×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C2b |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C3 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| S-RBD (Omicron XBB.1) in complex with PD of ACE2 |
Heteromer P0DTC2; | 6×NAG; 1×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron XBB.1) in complex with PD of ACE2 |
Heteromer P0DTC2; | 38×NAG; 28×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron BF.7) in complex with PD of ACE2 |
Heteromer P0DTC2; | 38×NAG; 28×NAG; | ||||
| Assess | ||||||
| S-RBD (Omicron BF.7) in complex with PD of ACE2 |
Heteromer P0DTC2; | 6×NAG; 1×NAG; | ||||
| Assess | ||||||
| S-RBD(Omicron BA.3) in complex with PD of ACE2 |
Heteromer P0DTC2; | 6×NAG; 1×NAG; | ||||
| Assess | ||||||
| S-RBD (Omicron BA.2.75) in complex with PD of ACE2 |
Heteromer P0DTC2; | 6×NAG; 1×NAG; | ||||
| Assess | ||||||
| S-ECD (Omicron BA.2.75) in complex with PD of ACE2 |
Heteromer P0DTC2; | 37×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state1) |
Heteromer P0DTC2; | 9×NAG; 1×ZN; 1×CL; 49×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state2) |
Heteromer P0DTC2; | 9×NAG; 53×NAG; 2×ZN; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in C2b state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| ACE2-RBD in SARS-CoV-2 Beta variant S-ACE2 complex |
Heteromer P0DTC2; | 1×ZN; 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in C3 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| The structures of Ace2 in complex with bicyclic peptide inhibitor |
Heteromer | 1×ZN; 1×LFI; | ||||
| Assess | ||||||
| ACE2 in complex with bicyclic peptide inhibitor |
Heteromer | 1×LFI; | ||||
| Assess | ||||||
| The structures of Ace2 in complex with bicyclic peptide inhibitor |
Heteromer | 2×LFI; | ||||
| Assess | ||||||
| Crystal structure of chimeric omicron RBD (strain BA.2) complexed with human ACE2 |
Heteromer P0DTC2; | 2×NAG; 1×ZN; 1×CL; 5×NAG; 1×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2 |
Heteromer P0DTC2; | 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 spike receptor-binding domain with a G485R mutation in complex with human ACE2 |
Heteromer P0DTC2; | 1×NAG; 4×NAG; 3×EDO; 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (T2… |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 |
Heteromer P0DTC2; | 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of chimeric omicron RBD (strain BA.1) complexed with human ACE2 |
Heteromer | 2×NAG; 5×NAG; 1×ZN; 2×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2 |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2 |
Heteromer P0DTC2; P59594; | 3×NAG; 2×NAG; 1×ZN; 1×CL; 1×EDO; 1×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (S1… |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| Crystal structure of Omicron BA.3 RBD complexed with hACE2 |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 1×NAG; 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Beta RBD in complex with human ACE2 and S304 Fab and S309 Fab |
Heteromer P0DTC2; | 2×NAG; 30×EDO; 22×CL; 2×ZN; 13×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Gamma variant receptor-binding domain complexed with high affinity human AC… |
Heteromer P0DTC2; | 1×ZN; 1×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2 |
Heteromer P0DTC2; | 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of chimeric omicron RBD (strain XBB.1) complexed with human ACE2 |
Heteromer P59594; | 2×NAG; 3×NAG; 1×ZN; 1×CL; 1×EDO; 1×NAG; | ||||
| Assess | ||||||
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immuni… |
Heteromer P0DTC2; | 1×NAG; 8×CL; 1×SO4; 4×NA; 1×PG5; 1×ZN; 4×NAG; 1×PGE; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2 |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2 |
Heteromer P0DTC2; | 1×NAG; 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2.75 RBD in complex with ACE2 |
Heteromer P0DTC2; | 12×GOL; 6×NAG; 1×CL; 1×PGE; | ||||
| Assess | ||||||
| Crystal structure of Omicron BA.2 RBD complexed with hACE2 |
Heteromer P0DTC2; | 1×NAG; 2×NAG; 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2 |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of human ACE2 bound to the spike receptor-binding domain from a cave bat sarbecov… |
Heteromer P0DTC2; | 1×NAG; 6×NAG; 4×SO4; 1×TRS; 5×PEG; 1×ZN; 2×CL; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein i… |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of Omicron BA.1.1 RBD complexed with hACE2 |
Heteromer P0DTC2; | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of chimeric omicron RBD (strain XBB.1.5) complexed with human ACE2 |
Heteromer P59594; | 2×NAG; 1×NAG; 1×ZN; 1×CL; 3×NAG; | ||||
| Assess | ||||||
| Structural basis of SARS-CoV-2-closely-related bat coronavirus RaTG13 to hACE2 |
Heteromer A0A6B9WHD3; | 2×NAG; 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human … |
Heteromer Q6Q1S2; | 8×NAG; | ||||
| Assess | ||||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant spike glycoprotein in … |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.4/5 variant spike protein… |
Heteromer P0DTC2; | 2×NAG; 2×NAG; 1×ZN; 1×NAG; | ||||
| Assess | ||||||
| The crystal structure of RshSTT182/200 RBD-insert2-T346R-Y496G mutant in complex with human ACE2 |
Heteromer | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| The complex structure of RshSTT182/200 RBD-insert2 bound to human ACE2 |
Heteromer | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state) |
Heteromer P0DTC2; | 8×NAG; 1×NAG; 1×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer P0DTC2; | 23×NAG; 24×NAG; 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2 |
Heteromer P0DTC2; | 2×NAG; 1×NAG; 1×NAG; 3×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 (focused… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2)… |
Heteromer P0DTC2; | 5×NAG; 3×NAG; | ||||
| Assess | ||||||
| Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer P0DTC2; | 4×NAG; 48×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with human ACE2 ectodomain (local refinement) |
Heteromer P0DTC2; | 1×NAG; 1×ZN; 6×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of human ACE2 complexed with SARS-CoV-2 Omicron RBD |
Heteromer P0DTC2; | 4×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer P0DTC2; | 31×NAG; 13×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 |
Heteromer P0DTC2; | 6×NAG; 44×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region |
Heteromer P0DTC2; | 1×ZN; 4×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzym… |
Heteromer P0DTC2; | 29×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 42×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer P0DTC2; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer P0DTC2; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with human ACE2 (local refinement) |
Heteromer P0DTC2; | 1×ZN; 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 (focused re… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 (focused refin… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (AC… |
Heteromer P0DTC2; | 3×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… |
Heteromer P0DTC2; | 15×NAG; 33×NAG; 3×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Kappa variant (B.1.617.1) RBD and Angiotensin-converting enzyme 2 … |
Heteromer P0DTC2; | 2×NAG; 1×NAG; 4×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state) |
Heteromer P0DTC2; | 9×NAG; 2×NAG; 2×NAG; 42×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer P0DTC2; | 18×NAG; 32×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2 |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 1×NAG; 4×NAG; | ||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Delta variant (B.1.617.2) RBD and Angiotensin-converting enzyme 2 … |
Heteromer P0DTC2; | 1×NAG; 4×NAG; 3×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer P0DTC2; | 37×NAG; 15×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enz… |
Heteromer P0DTC2; | 31×NAG; 17×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer P0DTC2; | 22×NAG; 23×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 (focused r… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state) |
Heteromer P0DTC2; | 8×NAG; 1×NAG; 1×NAG; 35×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer P0DTC2; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer P0DTC2; | 43×NAG; 14×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 (focused… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… |
Heteromer P0DTC2; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer P0DTC2; | 6×NAG; 56×NAG; | ||||
| Assess | ||||||
| ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2… |
Heteromer P0DTC2; | 2×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer P0DTC2; | 5×NAG; 46×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer P0DTC2; | 38×NAG; 16×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer P0DTC2; | 30×NAG; 1×NAG; 19×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.12.1 RBD in complex with human ACE2 (local refinement) |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 |
Heteromer P0DTC2; | 4×NAG; 53×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer P0DTC2; | 29×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement) |
Heteromer P0DTC2; | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… |
Heteromer P0DTC2; | 18×NAG; 42×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer P0DTC2; | 37×NAG; 13×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer P0DTC2; | 30×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2 |
Heteromer P0DTC2; | 6×NAG; 36×NAG; 3×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… |
Heteromer P0DTC2; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer P0DTC2; | 8×NAG; 55×NAG; | ||||
| Assess | ||||||
| BA.2(S375) Spike (S6P)/hACE2 complex |
Heteromer P0DTC2; | 3×NAG; 51×NAG; | ||||
| Assess | ||||||
| Local refinement of RBD-ACE2 |
Heteromer P0DTC2; | 1×NAG; 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| The structures of Ace2 in complex with bicyclic peptide inhibitor |
Heteromer | 2×ZN; 1×LFI; | ||||
| Assess | ||||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein… |
Heteromer P0DTC2; | 3×NAG; 1×NAG; 1×NAG; 1×ZN; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of chimeric omicron RBD (strain BA.2) complexed with chimeric mouse ACE2 |
Heteromer P0DTC2; | 1×NAG; 1×ZN; 1×CL; 3×NAG; 5×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron RBD in complex with human ACE2 and S304 Fab and S309 Fab |
Heteromer P0DTC2; | 4×EDO; 11×CL; 1×ZN; 6×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound |
Heteromer P0DTC2; | 23×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 RBD-62 in complex with ACE2 peptidase domain |
Heteromer P0DTC2; | 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (focused refinemen… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| BA.4/5 SARS-CoV-2 Spike bound to human ACE2 (local) |
Heteromer P0DTC2; | 6×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two human ACE2 Bound |
Heteromer P0DTC2; | 39×NAG; 2×CL; 2×ZN; | ||||
| Assess | ||||||
| The second RBD of SARS-CoV-2 Omicron Variant in complexed with RBD-ACE2 |
Heteromer P0DTC2; | 2×NAG; 1×CL; 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BQ.1.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody F… |
Heteromer P0DTC2; | 1×NAG; 5×NAG; 1×ZN; | ||||
| Assess | ||||||
| Furin Cleaved Alpha Variant SARS-CoV-2 Spike in complex with 3 ACE2 |
Heteromer P0DTC2; | 3×NAG; 48×NAG; 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three human ACE2 Bound |
Heteromer P0DTC2; | 39×NAG; 3×CL; 3×ZN; | ||||
| Assess | ||||||
| Dissociated S1 domain of Mink Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer P0DTC2; | 1×ZN; 6×NAG; | ||||
| Assess | ||||||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer P0DTC2; | 1×ZN; 8×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with T-ACE2 |
Heteromer P0DTC2; | 35×NAG; 34×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant RBD complexed with human ACE2 |
Heteromer P0DTC2; | 1×CL; 1×ZN; 3×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer P0DTC2; | 14×NAG; 12×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound) |
Heteromer P0DTC2; | 27×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant SPIKE trimer complexed with ACE2 |
Heteromer P0DTC2; | 12×NAG; 21×NAG; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 |
Heteromer P0DTC2; | 1×ZN; 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293 |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and … |
Heteromer P0DTC2; | 27×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 (focused refi… |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant RBD complexed with ACE2 |
Heteromer P0DTC2; | 3×NAG; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer P0DTC2; | 1×NAG; 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer P0DTC2; | 14×NAG; 20×NAG; | ||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and … |
Heteromer P0DTC2; | 32×NAG; 29×NAG; | ||||
| Assess | ||||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) |
Heteromer P0DTC2; | 1×NAG; 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound) |
Heteromer P0DTC2; | 26×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and … |
Heteromer P0DTC2; | 32×NAG; 29×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 18×NAG; 34×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 B.1.1.7 S-ACE2 complex |
Heteromer P0DTC2; | 16×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432 |
Heteromer P0DTC2; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 (focused refinemen… |
Heteromer P0DTC2; | 2×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 |
Heteromer P0DTC2; | 24×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-COV-2 Spike RBDMACSp36 binding to hACE2 |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 XBB.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fa… |
Heteromer P0DTC2; | 1×NAG; 5×NAG; | ||||
| Assess | ||||||
| Neutral Omicron Spike Trimer in complex with ACE2 |
Heteromer P0DTC2; | 16×NAG; 5×NAG; 34×NAG; | ||||
| Assess | ||||||
| XBB.1.5.10 RBD in complex with ACE2 |
Heteromer P0DTC2; | 4×NAG; | ||||
| Assess | ||||||
| Neutral Omicron Spike Trimer in complex with ACE2. |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 XBB.1.5.70 in complex with ACE2 |
Heteromer P0DTC2; | 4×NAG; | ||||
| Assess | ||||||
| XBB.1.5 spike protein in complex with ACE2 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| XBB.1.5.10 spike protein in complex with ACE2 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| XBB.1.5.70 spike protein in complex with ACE2 |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| Dissociated S1 domain of Beta Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer P0DTC2; | 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| XBB.1.5 RBD in complex with ACE2 |
Heteromer P0DTC2; | 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound |
Heteromer P0DTC2; | 20×NAG; 40×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound |
Heteromer P0DTC2; | 24×NAG; 42×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound |
Heteromer P0DTC2; | 17×NAG; 36×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(interface) |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| The co-crystal structure of ACE2 with Fab |
Heteromer | 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein with ACE2, C1 state |
Heteromer P0DTC2; | |||||
| Assess | ||||||
| SARS-CoV-2 BN.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab… |
Heteromer P0DTC2; | 1×NAG; 5×NAG; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from the 2002-2003 SARS coronavirus huma… |
Heteromer P59594; Q56NL1; | 5×NDG; 2×ZN; 2×CL; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from the 2005-2006 SARS coronavirus cive… |
Heteromer P59594; Q56NL1; | 5×NDG; 2×ZN; 2×CL; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of spike protein receptor-binding domain from SARS coronavirus epidemic strain co… |
Heteromer P59594; Q56NL1; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| SARS Spike Glycoprotein - human ACE2 complex, Stabilized variant, all ACE2-bound particles |
Heteromer P59594; | 9×NAG; 7×NAG; 11×NAG; 6×NAG; | ||||
| Assess | ||||||
| Importin alpha bound to the C-terminus of ACE2 |
Heteromer P52293; | |||||
| Assess | ||||||
| ACE2-peptide 2 complex | monomer | 1×NAG; 1×NAG; 3×GOL; 1×NAG; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| ACE2-peptide 1 complex | monomer | 3×NAG; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| ACE2-peptide 2 complex crystal form 3 | monomer | 1×NAG; 3×NAG; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Cryo-EM structure of ACE2 | monomer | |||||
| Assess | ||||||
| Cryo-EM structure of ACE2 | monomer | |||||
| Assess | ||||||
| ACE2-peptide 6 complex | monomer | 2×NAG; 5×GOL; 1×NAG; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| ACE2-peptide2 complex crystal form 2 | monomer | 3×NAG; 1×ZN; 2×NAG; 1×CL; | ||||
| Assess | ||||||
| NMR structure of human ACE2 21-42 fragment in HFIP/water 50/50 v/v | monomer | |||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6m17.1.B | monomer | 0.84 | 1×NAG; 1×ZN; | 100.00 | ||
| Assess | ||||||
| 7mjm.1 |
Heteromer Q9BYF1; P0DTC2; | 0.77 | 99.45 | |||
| Assess | ||||||
| 7kj2.1 |
Heteromer P0DTC2; | 0.72 | 4×NAG; 10×NAG; | 99.67 | ||
| Assess | ||||||
1 SWISS-MODEL model built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 3 | 7l7f.1.A | monomer | 0.73 | 99.12 | ||
| Assess | ||||||